Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multi-centre, Sequential Design, Phase IIa Study to Evaluate Safety and Tolerability of Epicardial Injections of AZD8601 During Coronary Artery Bypass Grafting Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs AZD 8601 (Primary) ; AZD 8601 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Acronyms EPICCURE
- Sponsors AstraZeneca; AstraZeneca AB
- 01 Mar 2023 Results assessing safety of AZD8601 in in patients undergoing coronary artery bypass grafting, published in the Molecular Therapy.
- 15 Nov 2021 Results presented in an AstraZeneca media release.
- 15 Nov 2021 Results presented in a Moderna Therapeutics media release.